多学科团队讨论对遗传性肺纤维化的影响
这项前瞻性研究纳入115例转诊至遗传多学科讨论(geneMDD)的患者,评估geneMDD对遗传结论、肺部诊断和治疗的影响。geneMDD后,2个致病性变异被重新分类为意义不明变异或良性,2个意义不明变异被重新分类为可能致病/致病;30例患者治疗方案发生改变。与治疗改变相关的因素包括肺部诊断和存在致病/可能致病性变异。
要点
- geneMDD可影响家族性肺纤维化患者的治疗决策。
- geneMDD后30例患者治疗方案发生改变。
- 治疗改变与肺部诊断及致病/可能致病性变异相关。
核心结论
- geneMDD可能影响家族性肺纤维化患者的治疗。
研究设计与样本
- 前瞻性研究,纳入所有连续转诊至geneMDD的患者,共115例。
主要发现
- geneMDD前,107例中82例检出罕见变异,其中65个分类为致病/可能致病。
- geneMDD后,2个致病性变异(3%)被重新分类为意义不明变异(n=1)或良性(n=1)。
- 17个初始意义不明变异中,2个(11.8%)被重新分类为可能致病/致病。
- 所有患者肺部诊断得到确认,不可分类肺纤维化最常见(n=38,33.0%)。
- geneMDD后30例患者治疗方案改变,相关因素包括肺部诊断和存在致病/可能致病性变异。
临床怎么用
- 对家族性肺纤维化患者可考虑经geneMDD讨论以优化诊断与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Approximately 30% of individuals diagnosed with familial pulmonary fibrosis (FPF) exhibit a pathogenic variant upon genetic analysis. We established a genetic Multidisciplinary Discussion (geneMDD) aimed to enhance expertise in diagnosing and managing FPF. This study aimed at prospectively evaluating the impact of geneMDD on diagnosis and treatment in patients referred to geneMDD. METHODS: In this prospective study, we enrolled all consecutive patients referred to the geneMDD. At each meeting, the impact of the meeting was questioned on the genetic conclusion, the pulmonary diagnosis, and the treatment. RESULTS: A total of 115 patients were included. Before geneMDD, rare variants were detected in 82 out of 107 patients, among which 65 variants were classified as pathogenic/likely pathogenic. Following geneMDD, 2 pathogenic variants (3%) were reclassified as variants of uncertain significance (VUS) (n = 1) or benign (n = 1). Among the 17 variants initially classified as VUS, 2 (11.8%) were reclassified as likely pathogenic/pathogenic. The pulmonary diagnosis was confirmed for all patients (unclassifiable lung fibrosis was the more frequent diagnosis, n = 38, 33.0%). The therapeutic regimen was changed after geneMDD in 30 patients. Factors associated with therapeutic changes included the pulmonary diagnosis and presence of a pathogenic/likely pathogenic variant. In addition, the French health system allows offering whole genome sequencing (WGS) in patients with a first negative genetic analysis by NGS panel after discussion in geneMDD, but in total, since September 1st, 2021, WGS was negative for the four analysed families. CONCLUSION: This study suggests that geneMDD could influence the treatment of FPF patients.
引用
- Franco G, Ba I, Nathan N, et al. Impact of A Multidisciplinary Team Discussion for Genetic Lung Fibrosis. Respirology. 2025. PMID: 40134350. doi:10.1111/resp.70039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。